Altered Meg3 levels have also been identified in blood of patients with Parkinson’s disease, clinically diagnosed psychosis, and schizophrenia, suggesting the possible use of Meg3 as a novel biomarker in human brain disorders [32–34]. The gene discussed is MEG3; the disease is schizophrenia.